New Intermittent Pneumatic Compression Device for Treatment of Symptoms of Peripheral Artery Disease Launched by Mego Afek
By Mego Afek Ac Ltd., PRNEThursday, November 18, 2010
Angio Press May Help Patients Retain or Regain Mobility
DUSSELDORF, Germany and HAIFA, Israel, November 19, 2010 - A new intermittent pneumatic compression device for enhanced blood
circulation in patients diagnosed with peripheral artery disease (PAD), is
being launched by Mego Afek AC, Ltd. here at the MEDICA World Forum for
Medicine.
The Angio Press(R) provides moderately applied high-pneumatic pressure
through pressure garments that are filled with air in an intermittent
sequence from the feet and ankles up through the calves of patients diagnosed
with PAD. At the end of the sequence, pressure is blocked for four seconds
and released when the garments are deflated, followed by a 40-second
pressure-free interval.
This intermittent pneumatic compression has been demonstrated to be an
effective method for the prevention of deep vein thrombosis and lymphedema.
Preliminary results of clinical studies with Angio Press have demonstrated
improvement in the symptoms of patients with lower extremity PAD, which may
help patients to improve blood flow to their legs, thereby maintaining or
improving their mobility.
"Conservative treatment is preferred in cases of intermittent
claudicating patients maintaining invasive treatment to sever ischemia of the
limbs. Angio Press may provide physicians an important additional treatment
modality for patients with stable, Stage II PAD," said Professor Avigdor
Zelikovsky, former head, vascular department, Rabin Medical Center, Israel.
"Non-invasive options such as this one may allow patients to retain, or in
many cases, regain their mobility without significant additional side
effects, and allow them to pursue a healthier lifestyle."
The availability of Angio Press is based on a multi-center, randomized,
controlled, four-arm open label study. According to data from 28 subjects in
Germany and Israel, patients in the treatment group received platelet
medication (either aspirin or clopidigrel), walking exercises and Angio Press
treatment either once daily for three hours or twice daily for 1.5 hours.
These patients demonstrated improvement in the distance at which they first
experienced pain when exerting themselves (initial claudication) from 75
meters at baseline to 145 meters after the three-month treatment period, a
mean improvement of 69 meters. This was compared to the control group, which
received medication and exercise regimen only, and demonstrated improvement
from 79.5 meters to 96 meters, a mean improvement of only 13 meters.
Other results included change in total distance walked until the patient
could no longer continue (absolute claudication), for which the treatment
group demonstrated a mean improvement of 62.5 meters, compared to the control
group, which demonstrated a worsening by a mean of 12 meters.
There were no serious adverse events in either study group, although
slight discomfort was reported by two subjects when their initial treatment
pressure was set to 120mm/Hg. This was improved following pressure adjustment
by the physician.
"Angio Press applies our established science in enhancing blood flow and
pain reduction," said Yossi Mazel, vice president, sales and marketing, Mego
Afek. "We are now able to offer practitioners a wider array of intermittent
pneumatic compression solutions to help more of their patients improve their
quality of life."
About Peripheral Artery Disease
Peripheral artery disease is defined as a pathologic blood flow
obstruction in arteries exclusive of the coronary and cerebral vessels. It
occurs when the arteries in the feet, legs, hands and arms become clogged
with plaque, which causes them to become narrow and hard, obstructing blood
flow. The hardening of these arteries is called atherosclerosis, and may
damage tissue by depriving it of blood, and thereby oxygen and nutrients. The
condition is both preventable and treatable.
About Mego Afek AC, Ltd.
Mego Afek specializes in manufacture of non-invasive medical devices,
pressure control systems and high-frequency welded products including
inflatable structures and components.
The Medical Division produces non-invasive medical compression therapy
systems for treatment of lymphatic / circulatory disorders and deep vein
thrombosis prophylaxis; aesthetic massage therapy systems; and stationary
exercise devices for circulatory enhancement. Product lines include our
world-renowned Lympha Press(R) compression therapy systems, Phlebo Press,
Plebo Press DVT and Ballancer(R) systems for aesthetic lymphatic massage
Mego Afek's products are sold worldwide through a well-established
network of distributors. Our medical and aesthetic products are sold in over
30 countries in Europe, Asia, the Americas, the Middle East, and Africa.
Angio Press, Lympha Press and Ballancer are registered trademarks of Mego
Afek AC, Ltd.
Jules Abraham, Feintuch Communications, +1-212-808-4904, jules at feintuchpr.com
Tags: Dusseldorf, Europe, Germany And Haifa, Israel, Mego Afek Ac Ltd., November 19